The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination

The human papillomavirus (HPV) vaccine was initially approved for a three-dose regimen. Due to resource limitations, budget constraints, low acceptance, and poor adherence, global vaccination coverage is only 15%. A single-dose regimen could simplify logistics, reduce costs, and improve accessibilit...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2024-09, Vol.12 (9), p.956
Main Authors: Bao, Wanying, He, Xinlin, Huang, Yue, Liu, Rongyu, Li, Zhengyu
Format: Article
Language:English
Subjects:
Abnormalities
Age groups
Carcinogens
Cervical cancer
Clinical outcomes
Clinical trials
Cohort analysis
Cross-sectional studies
dose
Drug dosages
Effectiveness
Human papillomavirus
Immunization
Infection
Infections
Medical research
Medicine, Experimental
Papillomaviruses
Review
Vaccination
vaccine
Vaccines
Warts
Women
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The human papillomavirus (HPV) vaccine was initially approved for a three-dose regimen. Due to resource limitations, budget constraints, low acceptance, and poor adherence, global vaccination coverage is only 15%. A single-dose regimen could simplify logistics, reduce costs, and improve accessibility. However, its clinical effectiveness remains debatable. This review systematically searched PubMed, Embase, and Cochrane Library, including 42 clinical studies, to assess the effectiveness of a single-dose HPV vaccination for preventing HPV infections, cervical abnormalities, and genital warts. We summarized the effectiveness of bivalent, quadrivalent, and nonavalent vaccines across different age groups and buffer periods, and analyzed the factors contributing to the inconsistency of results. The review also provides insights into designing robust future research to inform single-dose HPV vaccination policies and guidelines, highlighting the need for further research to refine vaccination strategies.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines12090956